UK government denies levy scheme for branded medicines is causing shortages
The British Generic Manufacturers Association has argued that the voluntary scheme for branded medicines pricing and access rebate rate is a “key factor” behind a rise in shortages of branded generic medicines.
The VPAS rebate for branded medicines was 5.1% in 2021 but it has risen to 26.5% in 2023
SCIENCE PHOTO LIBRARY
The UK government has denied that rising levies on branded medicines has led to shortages of branded generic medicines.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
